Latest / The High Net Worth Podcast with Fexingo: Wealth Management, Tax Strategy, and Affluent Finance
Family Offices Betting On Biofoundries
We explore how ultra-high-net-worth family offices are moving beyond traditional biotech equity into direct ownership of biofoundries—the automated labs that serve as the hardware for synthetic biology. With companies like Ginkgo Bioworks raising capital and the broader sector facing valuation pressure, we examine why families are structuring bespoke partnerships with these platforms rather than just buying stock. We look at the specific economics of lab access versus IP licensing, the operational risks of biological manufacturing, and the long-term play in programmable cells. This is a deep…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.